1. Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg. 2003;61:1115-7.

https://doi.org/10.1016/S0278-2391(03)00720-1

PMid:12966493 

2. Ruggiero SL, Fantasia J, Carlson E. Bisphosphonate-related osteonecrosis of the jaw: background and guidelines for diagnosis, staging and management. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2006;102:433-41.

https://doi.org/10.1016/j.tripleo.2006.06.004

PMid:16997108 

3. Marx RE, Sawatari Y, Fortin M, Broumand V. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg. 2005;63:1567-75.

https://doi.org/10.1016/j.joms.2005.07.010

PMid:16243172 

4. Beth-Tasdogan NH, Mayer B, Hussein H, Zolk O. Interventions for managing medication-related osteonecrosis of the jaw. Cochrane Database Syst Rev. 2017;10:CD012432.

https://doi.org/10.1002/14651858.CD012432.pub2

PMid:28983908 PMCid:PMC6485859

5. Ruggiero SL, Dodson TB, Aghaloo T, Carlson ER, Ward BB, Kademani D. American Association of Oral and Maxillofacial Surgeons' Position Paper on Medication-Related Osteonecrosis of the Jaws-2022 Update. J Oral Maxillofac Surg. 2022;80:920-43.

https://doi.org/10.1016/j.joms.2022.02.008

PMid:35300956 

6. Ehrenstein V, Heide-Jørgensen U, Schiødt M, Akre O, Herlofson BB, Hansen S, et al. Osteonecrosis of the jaw among patients with cancer treated with denosumab or zoledronic acid: Results of a regulator-mandated cohort postauthorization safety study in Denmark, Norway, and Sweden. Cancer. 2021;127:4050-8.

https://doi.org/10.1002/cncr.33802

PMid:34310704 

7. Egloff-Juras C, Gallois A, Salleron J, Massard V, Dolivet G, Guillet J, et al. Denosumab-related osteonecrosis of the jaw: A retrospective study. J Oral Pathol Med. 2018;47:66-70.

https://doi.org/10.1111/jop.12646

PMid:28977694 

8. Eguia A, Bagan L, Cardona F. Review and update on drugs related to the development of osteonecrosis of the jaw. Med Oral Patol Oral Cir Bucal. 2020;25:e71-83.

https://doi.org/10.4317/medoral.23191

PMid:31880288 PMCid:PMC6982985

9. Bone HG, Wagman RB, Brandi ML, Brown JP, Chapurlat R, Cummings SR, et al. 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension. Lancet Diabetes Endocrinol. 2017;5:513-23

https://doi.org/10.1016/S2213-8587(17)30138-9

PMid:28546097 

10. Khan AA, Morrison A, Hanley DA, Felsenberg D, McCauley LK, O'Ryan F, et al. Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. J Bone Miner Res. 2015;30:3-23.

https://doi.org/10.1002/jbmr.2405

PMid:25414052 

11. Goker F, Grecchi E, Grecchi F, Francetti L, Del Fabbro M. Treatment of medication-related osteonecrosis of the jaw (MRONJ). A systematic review. Eur Rev Med Pharmacol Sci. 2021;25:2662-73.

PMid:33829453

12. Al-Hamed FS, Mahri M, Al-Waeli H, Torres J, Badran Z, Tamimi F. Regenerative Effect of Platelet Concentrates in Oral and Craniofacial Regeneration. Front Cardiovasc Med. 2019;6:126.

https://doi.org/10.3389/fcvm.2019.00126

PMid:31552270 PMCid:PMC6733887

13. Szentpeteri S, Schmidt L, Restar L, Csaki G, Szabo G, Vaszilko M. The Effect of Platelet-Rich Fibrin Membrane in Surgical Therapy of Medication-Related Osteonecrosis of the Jaw. J Oral Maxillofac Surg. 2020;78:738-48.

https://doi.org/10.1016/j.joms.2019.12.008

PMid:31945309 

14. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.

https://doi.org/10.1136/bmj.n71

PMid:33782057 PMCid:PMC8005924

15. Higgins JPT, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.

https://doi.org/10.1136/bmj.d5928

PMid:22008217 PMCid:PMC3196245

16. Sterne JA, Hernán MA, Reeves BC, Savović J, Berkman ND, Viswanathan M, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016;355:i4919.

https://doi.org/10.1136/bmj.i4919

PMid:27733354 PMCid:PMC5062054

17. Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21:1539-58.

https://doi.org/10.1002/sim.1186

PMid:12111919 

18. Egger M, Smith GD, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629-34.

https://doi.org/10.1136/bmj.315.7109.629

PMid:9310563 PMCid:PMC2127453

19. Lafuente Ibáñez de Mendoza I, Lorenzo Pouso AI, Aguirre Urízar JM, Barba Montero C, Blanco Carrión A, Gándara Vila P, et al. Malignant development of proliferative verrucous/multifocal leukoplakia: A critical systematic review, meta-analysis and proposal of diagnostic criteria. J Oral Pathol Med. 2022;51:30-8.

https://doi.org/10.1111/jop.13246

PMid:34558734 

20. Park JH, Kim JW, Kim SJ. Does the Addition of Bone Morphogenetic Protein 2 to Platelet-Rich Fibrin Improve Healing After Treatment for Medication-Related Osteonecrosis of the Jaw? J Oral Maxillofac Surg. 2017;75:1176-84.

https://doi.org/10.1016/j.joms.2016.12.005

PMid:28042979 

21. Kim JW, Kim SJ, Kim MR. Leucocyte-rich and platelet-rich fibrin for the treatment of bisphosphonate-related osteonecrosis of the jaw: a prospective feasibility study. Br J Oral Maxillofac Surg. 2014;52:854-9.

https://doi.org/10.1016/j.bjoms.2014.07.256

PMid:25138613 

22. Nørholt SE, Hartlev J. Surgical treatment of osteonecrosis of the jaw with the use of platelet-rich fibrin: a prospective study of 15 patients. Int J Oral Maxillofac Surg. 2016;45:1256-60.

https://doi.org/10.1016/j.ijom.2016.04.010

PMid:27179556 

23. Zelinka J, Blahak J, Perina V, Pacasova R, Treglerova J, Bulik O. The use of platelet-rich fibrin in the surgical treatment of medication-related osteonecrosis of the jaw: 40 patients prospective study. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2021;165:322-7.

https://doi.org/10.5507/bp.2020.023

PMid:32597421 

24. Özalp Ö, Yıldırımyan N, Öztürk C, Kocabalkan B, Şimşek Kaya G, Sindel A, et al. Promising results of surgical management of advanced medication related osteonecrosis of the jaws using adjunctive leukocyte and platelet rich fibrin. BMC Oral Health. 2021;21:613.

https://doi.org/10.1186/s12903-021-01965-7

PMid:34852823 PMCid:PMC8638116

25. Şahin O, Akan E, Tatar B, Ekmekcioğlu C, Ünal N, Odabaşı O. Combined approach to treatment of advanced stages of medication-related osteonecrosis of the jaw patients. Braz J Otorhinolaryngol. 2022;88:613-20.

https://doi.org/10.1016/j.bjorl.2021.04.004

PMid:34023243 PMCid:PMC9422660

26. Valente NA, Chatelain S, Alfonsi F, Mortellaro C, Barone A. Medication-Related Osteonecrosis of the Jaw: The Use of Leukocyte-Platelet-Rich Fibrin as an Adjunct in the Treatment. J Craniofac Surg. 2019;30:1095-101.

https://doi.org/10.1097/SCS.0000000000005475

PMid:30908443 

27. Tenore G, Zimbalatti A, Rocchetti F, Graniero F, Gaglioti D, Mohsen A, et al. Management of Medication-Related Osteonecrosis of the Jaw (MRONJ) Using Leukocyte- and Platelet-Rich Fibrin (L-PRF) and Photobiomodulation: A Retrospective Study. J Clin Med. 2020;9:1-16.

https://doi.org/10.3390/jcm9113505

PMid:33138266 PMCid:PMC7693575

28. Fernando de Almeida Barros Mourão C, Calasans-Maia MD, Del Fabbro M, Le Drapper Vieira F, Coutinho de Mello Machado R, Capella R, et al. The use of Platelet-rich Fibrin in the management of medication-related osteonecrosis of the jaw: A case series. J Stomatol Oral Maxillofac Surg. 2020;121:84-9.

https://doi.org/10.1016/j.jormas.2019.02.011

PMid:30794883 

29. Viechtbauer W, Cheung MW-L. Outlier and influence diagnostics for meta-analysis. Res Synth Methods. 2010;1:112-25.

https://doi.org/10.1002/jrsm.11

PMid:26061377 

30. Yarom N, Shapiro CL, Peterson DE, Van Poznak CH, Bohlke K, Ruggiero SL, et al. Medication-Related Osteonecrosis of the Jaw: MASCC/ISOO/ASCO Clinical Practice Guideline. J Clin Oncol. 2019;37:2270-90.

https://doi.org/10.1200/JCO.19.01186

PMid:31329513 

31. Govaerts D, Piccart F, Ockerman A, Coropciuc R, Politis C, Jacobs R. Adjuvant therapies for MRONJ: A systematic review. Bone. 2020;141:115676.

https://doi.org/10.1016/j.bone.2020.115676

PMid:33022455 

32. Lopez-Jornet P, Sanchez Perez A, Amaral Mendes R, Tobias A. Medication-related osteonecrosis of the jaw: Is autologous platelet concentrate application effective for prevention and treatment? A systematic review. J Craniomaxillofac Surg. 2016;44:1067-72.

https://doi.org/10.1016/j.jcms.2016.05.004

PMid:27318752 

33. Lorenzo‐pouso AI, Bagán J, Bagán L, Gándara‐vila P, Chamorro‐petronacci CM, Castelo‐baz P, et al. Medication-Related Osteonecrosis of the Jaw: A Critical Narrative Review. J Clin Med. 2021;10:4367.

https://doi.org/10.3390/jcm10194367

PMid:34640383 PMCid:PMC8509366

34. Di Fede O, Canepa F, Panzarella V, Mauceri R, Del Gaizo C, Bedogni A, et al. The Treatment of Medication-Related Osteonecrosis of the Jaw (MRONJ): A Systematic Review with a Pooled Analysis of Only Surgery versus Combined Protocols. Int J Environ Res Public Health. 2021;18:8432.

https://doi.org/10.3390/ijerph18168432

PMid:34444181 PMCid:PMC8392050

35. Yoneda T, Hagino H, Sugimoto T, Ohta H, Takahashi S, Soen S, et al. Antiresorptive agent-related osteonecrosis of the jaw: Position Paper 2017 of the Japanese Allied Committee on Osteonecrosis of the Jaw. J Bone Miner Metab. 2017;35:6-19.

https://doi.org/10.1007/s00774-016-0810-7

PMid:28035494 

36. Momesso GAC, Lemos CAA, Santiago-Júnior JF, Faverani LP, Pellizzer EP. Laser surgery in management of medication-related osteonecrosis of the jaws: a meta-analysis. Oral Maxillofac Surg. 2020;24:133-44.

https://doi.org/10.1007/s10006-020-00831-0

PMid:32056052 

37. Mozzati M, Arata V, Gallesio G. Tooth extraction in patients on zoledronic acid therapy. Oral Oncol. 2012;48:817-21.

https://doi.org/10.1016/j.oraloncology.2012.03.009

PMid:22483860 

38. Asaka T, Ohga N, Yamazaki Y, Sato J, Satoh C, Kitagawa Y. Platelet-rich fibrin may reduce the risk of delayed recovery in tooth-extracted patients undergoing oral bisphosphonate therapy: a trial study. Clin Oral Investig. 2017;21:2165-72.

https://doi.org/10.1007/s00784-016-2004-z

PMid:27837344